The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Antelava O.A.

Kafedra revmatologii FPPOV GBOU VPO "Pervyĭ MGMU im. I.M. Sechenova" Minzdrava Rossii

Khelkovskaia-Sergeeva A.N.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Tarasova G.M.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Nikishina N.Iu.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Lopatina N.E.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Pal’shina S.G.

Laboratory of Intensive Therapy of Rheumatic Diseases, Federal state budgetary scientific institution «V.A. Nasonova Research Institute of Rheumatology», Moscow, Russia

Fedina T.P.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Sazhina E.G.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Use of anti-B-cell therapy in case of antisynthetase syndrome as the severest subtype of polymyositis/dermatomyositis

Authors:

Antelava O.A., Khelkovskaia-Sergeeva A.N., Tarasova G.M., Nikishina N.Iu., Lopatina N.E., Pal’shina S.G., Fedina T.P., Sazhina E.G.

More about the authors

Journal: Therapeutic Archive. 2014;86(5): 109‑115

Read: 3019 times


To cite this article:

Antelava OA, Khelkovskaia-Sergeeva AN, Tarasova GM, et al. . Use of anti-B-cell therapy in case of antisynthetase syndrome as the severest subtype of polymyositis/dermatomyositis. Therapeutic Archive. 2014;86(5):109‑115. (In Russ.)

Recommended articles:
Pathomorphological characteristics of inflammatory and here­ditary myopathies. Russian Journal of Archive of Pathology. 2025;(4):31-39

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.